Bli medlem
Bli medlem

Du är här

2016-11-04

Medigene AG: Medigene participates at six national and international conferences

Medigene AG / Medigene participates at six national and international
conferences. Processed and transmitted by Nasdaq Corporate Solutions. The
issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 4 November 2016.
Medigene AG(MDG1, Frankfurt, Prime Standard) announces its participation at
six upcoming scientific, investor and business development conferences:

* BioEurope

Date: 7 - 9 November 2016

Location: Cologne, Germany

* SITC 2016 - Society for Immunotherapy of Cancer

Date: 9 - 13 November 2016

Location: National Harbor, Maryland, USA

* Neoantigens Summit

Date: 15 - 17 November 2016

Location: Boston, USA
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk
on the topic: "Are we Limited to Treatment of Tumors with High-Mutational
Loads and Patients with Pre-Existing Neoantigen-Specific T Cells?"

* 6th Munich Biomarker Conference

Date: 29 - 30 November 2016

Location: Munich, Germany
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a
keynote talk on the topic: "From personalized to individualized medicine, the
next major step in developing the medicine of the future".

* EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Date: 29 November - 2 December 2016

Location: Munich, Germany

* ASH 2016 - The 58th American Society of Hematology Annual Meeting

Date: 3 - 6 December 2016

Location: San Diego, USA

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative, complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T
cell-based immunotherapies.

For more information, please visitwww.medigene.com

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email:investor@medigene.com

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor@medigene.com). We will then delete your address
from our distribution list.

Press release English PDF
http://hugin.info/132073/R/2054199/768977.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.